AIM ImmunoTech reports positive pancreatic cancer trial results, bolsters cash position.

• AIM ImmunoTech reports positive mid-year data for Ampligen in pancreatic cancer. • Combination with Imfinzi shows no significant toxicity and improved PFS and OS. • Bolstered cash position funds operations for approximately 12 months. • Focus on advancing Ampligen for pancreatic cancer treatment. • Goal is to achieve drug approval.

AIM ImmunoTech Inc. has released positive mid-year data from its ongoing phase 2 DURIPANC clinical study, which evaluates the combination of Ampligen (rintatolimod) and Imfinzi (durvalumab) for the treatment of metastatic pancreatic cancer patients post-FOLFIRINOX chemotherapy. The study, conducted in collaboration with AstraZeneca and Erasmus Medical Center, has demonstrated encouraging early signs of both a favorable safety profile and superior progression-free survival (PFS) and overall survival (OS).

The preliminary data from the study, which aims to enroll up to 25 patients, shows that 21% of patients (n = 3/14) have achieved PFS exceeding 6 months, with an additional 21% yet to experience disease progression. This early indication of prolonged disease control is noteworthy in metastatic pancreatic cancer, where rapid progression is common. Furthermore, 64% of patients have achieved OS greater than 6 months, which is considered better than expected in this aggressive disease setting. The combination therapy has also demonstrated no significant toxicity, indicating an encouraging safety profile for patients in a post-chemotherapy setting.

AIM ImmunoTech's focus on pancreatic cancer treatment with Ampligen spans several years. Since 2017, over 50 patients with pancreatic cancer have received Ampligen as an immuno-oncology monotherapy under a Dutch government-approved Compassionate Use/Early Access Program at Erasmus Medical Center. These earlier positive results laid the groundwork for the DURIPANC study, which was initiated in January 2023 through clinical agreements between AIM, AstraZeneca, and Erasmus Medical Center.

The company's robust cash position is expected to fund operations for approximately 12 months, allowing it to advance Ampligen for pancreatic cancer treatment. AIM ImmunoTech's goal is to achieve drug approval and position Ampligen as a potential game-changer in the treatment of pancreatic cancer, a disease setting historically challenging for therapeutic intervention.

The global pancreatic cancer market is projected to grow from $2.72 billion in 2025 to $13.01 billion by 2037, driven by rising incidence rates, aging populations, and advancements in immunotherapy. AIM's Ampligen is uniquely positioned to capture a significant share of this growth. The company holds orphan drug designations for Ampligen in pancreatic cancer in both the US and the European Union, which could grant years of market exclusivity post commercial approval.

References:
[1] AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer. News release. AIM ImmunoTech. July 28, 2025. Accessed July 29, 2025. https://tinyurl.com/yn6dy64n
[2] DURIPANC, Mid-Year Interim Clinical Progress Update. AIM ImmunoTech. Accessed July 29, 2025. https://tinyurl.com/4e8pys5p